Acute central effects of the calcium channel blocker and antiglutamatergic drug caroverine. Double-blind, placebo-controlled, EEG mapping and psychometric studies after intravenous and oral administration
- PMID: 7741773
Acute central effects of the calcium channel blocker and antiglutamatergic drug caroverine. Double-blind, placebo-controlled, EEG mapping and psychometric studies after intravenous and oral administration
Abstract
In a double-blind, placebo-controlled study, the effects of caroverine (CAS 23465-76-1, Spasmium)--a quinoxaline derived from isoquinoline, the basic structure of papaverine, originally developed as a spasmolytic drug which may, however, exert central effects due to an unspecific calcium channel blocking action and glutamate antagonism--were investigated utilizing EEG-mapping, psychometric and psychophysiological measures. Fifteen healthy volunteers (8 males and 7 females), aged 20-35 years, received randomized and at weekly intervals 40 and 80 mg caroverine intravenously, 40 and 80 mg caroverine orally, as well as placebo. EEG recordings, psychometric and psychophysiological tests, as well as evaluation of pulse, blood pressure and side-effects were carried out at 0, 1, 2, 4, 6 and 8 h. Multivariate analysis of EEG mapping data demonstrated that caroverine exerted a significant action on human brain function, as compared with placebo, at all given dosages, as early as in the 1st and as late as in the 8th hour after both intravenous and oral administration during resting (R-EEG) and vigilance-controlled recording (V-EEG). Subsequent univariate analyses revealed, however, differential effects of caroverine--dependent on recording conditions and doses. In the resting condition, an increase of absolute and relative delta and theta power, a decrease of alpha and beta power and a slowing of the centroid of the delta and theta activity occurred, reflecting sedative action. The latter was slightly time- and dose-dependent (more sedation in earlier hours after higher doses). However, in the vigilance-controlled EEG, a dose-dependent decrease of delta and theta power, an increase of alpha power and an acceleration of the centroid of the delta and theta suggested vigilance-promoting effects, which were more pronounced in the later than earlier hours. Psychometric investigations confirmed these differential central effects. In regard to the noopsyche, an improvement was noted 6 h after the lowest oral dose. In the thymopsyche, a deterioration occurred after all doses except the highest oral dose, suggesting sedation. The latter was also seen after all active compounds as a trend in psychophysiological variables. The drug was well tolerated.
Similar articles
-
Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry.Eur Neuropsychopharmacol. 2005 Oct;15(5):533-43. doi: 10.1016/j.euroneuro.2005.01.004. Eur Neuropsychopharmacol. 2005. PMID: 16046102 Clinical Trial.
-
Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: I. Double-blind, placebo-controlled EEG mapping and psychometric studies under normoxia.Methods Find Exp Clin Pharmacol. 1996 Jan-Feb;18(1):55-66. Methods Find Exp Clin Pharmacol. 1996. PMID: 8721257 Clinical Trial.
-
Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry.Pharmacopsychiatry. 1987 Feb;20(1 Spec No):12-27. doi: 10.1055/s-2007-1017125. Pharmacopsychiatry. 1987. PMID: 2883677 Clinical Trial.
-
Drug profiling by computed electroencephalography and brain maps, with special consideration of sertraline and its psychometric effects.J Clin Psychiatry. 1988 Aug;49 Suppl:59-71. J Clin Psychiatry. 1988. PMID: 2970456 Review.
-
Pharmacodynamics of nomifensine: a review of studies in healthy subjects.J Clin Psychiatry. 1984 Apr;45(4 Pt 2):33-8. J Clin Psychiatry. 1984. PMID: 6370972 Review.
Cited by
-
Hippocampal glutamate concentration predicts cerebral theta oscillations during cognitive processing.Psychopharmacology (Berl). 2006 Jul;187(1):103-11. doi: 10.1007/s00213-006-0397-0. Epub 2006 Apr 22. Psychopharmacology (Berl). 2006. PMID: 16767420
-
Blocking AMPA receptor signalling by caroverine infusion does not affect counter-regulation of hypoglycaemia in healthy men.Diabetologia. 2009 Jun;52(6):1192-6. doi: 10.1007/s00125-009-1343-6. Epub 2009 Apr 3. Diabetologia. 2009. PMID: 19343318 Clinical Trial.
-
Effect of oral caroverine in the treatment of tinnitus: A quasi-experimental study.J Family Med Prim Care. 2024 Oct;13(10):4648-4651. doi: 10.4103/jfmpc.jfmpc_617_24. Epub 2024 Oct 18. J Family Med Prim Care. 2024. PMID: 39629381 Free PMC article.
-
Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines.Eur Arch Otorhinolaryngol. 2015 Nov;272(11):3451-6. doi: 10.1007/s00405-014-3364-0. Epub 2014 Oct 29. Eur Arch Otorhinolaryngol. 2015. PMID: 25351499
-
PHARMACOLOGICAL TREATMENTS FOR TINNITUS: NEW AND OLD.Drugs Future. 2009;34(5):381-400. doi: 10.1358/dof.2009.034.05.1362442. Drugs Future. 2009. PMID: 21765586 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources